Alzheimer's

An 83-year-old woman with severe Alzheimer’s disease began speaking in full sentences and regained bladder control after taking a large dose of psilocybin. The changes occurred following a single session with the psychedelic compound derived from magic mushrooms. Researchers describe the case as dramatic but stress it is only one anecdotal report.

19 Mwezi wa sita, 2026 Imeripotiwa na AI

Researchers at the University of California, Riverside have proposed that amyloid beta disrupts tau protein function inside neurons, potentially triggering Alzheimer's disease. The findings challenge the focus on external plaques as the primary cause.

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

7 Mwezi wa nne, 2026 Imeripotiwa na AI

A new study has found that adults with higher vitamin D levels in their 30s and 40s tend to have lower levels of tau protein in their brains about 16 years later. Tau is a key biomarker associated with dementia. The research, published this week, highlights a potential modifiable risk factor for brain health.

Researchers at UCLA Health and UC San Francisco have identified a natural defense mechanism in brain cells that helps remove toxic tau protein, potentially explaining why some neurons resist Alzheimer's damage better than others. The study, published in Cell, used CRISPR screening on lab-grown human neurons to uncover this system. Findings suggest new therapeutic avenues for neurodegenerative diseases.

1 Mwezi wa tatu, 2026 Imeripotiwa na AI Imethibitishwa ukweli

Rice University scientists say they have created the first complete, label-free molecular atlas of an Alzheimer’s brain in an animal model, combining hyperspectral Raman imaging with machine learning to map chemical changes that appear unevenly across brain regions and extend beyond amyloid plaques.